135 related articles for article (PubMed ID: 35082165)
1. HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression.
Di Segni M; Virdia I; Verdina A; Amoreo CA; Baldari S; Toietta G; Diodoro MG; Mottolese M; Sperduti I; Moretti F; Buglioni S; Soddu S; Di Rocco G
Mol Cancer Res; 2022 May; 20(5):686-698. PubMed ID: 35082165
[TBL] [Abstract][Full Text] [Related]
2. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
3. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
4. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
5. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
D'Orazi G; Sciulli MG; Di Stefano V; Riccioni S; Frattini M; Falcioni R; Bertario L; Sacchi A; Patrignani P
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):735-41. PubMed ID: 16467083
[TBL] [Abstract][Full Text] [Related]
6. Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer.
Zhou L; Feng Y; Jin Y; Liu X; Sui H; Chai N; Chen X; Liu N; Ji Q; Wang Y; Li Q
BMC Cancer; 2014 Oct; 14():747. PubMed ID: 25282590
[TBL] [Abstract][Full Text] [Related]
7. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
9. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
10. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
12. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
13. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
14. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
15. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.
Qin Y; Hu Q; Ji S; Xu J; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Yu X; Zhang B; Xu X
Cell Prolif; 2019 May; 52(3):e12603. PubMed ID: 30932257
[TBL] [Abstract][Full Text] [Related]
16. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
[TBL] [Abstract][Full Text] [Related]
17. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H
Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816
[TBL] [Abstract][Full Text] [Related]
18. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
[TBL] [Abstract][Full Text] [Related]
20. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
